 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 November 1999 | Volume 131 Issue 9 | Pages 660-667
Background: Although guidelines recommend angiotensin-converting enzyme inhibitors for diabetic patients with microalbuminuria, this strategy requires that providers adhere to screening recommendations. In addition, the benefit of angiotensin-converting enzyme inhibitors in normoalbuminuric patients was recently demonstrated.
Objective: To evaluate the cost-effectiveness of treating all patients with type 2 diabetes.
Design: Markov model simulating the progression of diabetic nephropathy.
Data Sources: Randomized trials estimating the progression of diabetic nephropathy with and without angiotensin-converting enzyme inhibitors.
Target Population: Patients 50 years of age with newly diagnosed type 2 diabetes (fasting plasma glucose level
Time Horizon: Lifetime.
Perspective: Societal.
Interventions: Patients received angiotensin-converting enzyme inhibitors, screening for microalbuminuria, or screening for gross proteinuria.
Outcome Measures: Lifetime cost, quality-adjusted life expectancy, and marginal cost-effectiveness.
Results of Base-Case Analysis: Screening for gross proteinuria had the highest cost and the lowest benefit. Compared with screening for microalbuminuria, treating all patients was more expensive ($15 240 and $14 940 per patient) but was associated with increased quality-adjusted life expectancy (11.82 and 11.78 quality-adjusted life-years). The marginal cost-effectiveness ratio was $7500 per quality-adjusted life-year gained.
Results of Sensitivity Analysis: Results were sensitive to the cost, effectiveness, and quality of life associated with angiotensin-converting enzyme inhibitor therapy, as well as age at diagnosis. The model was relatively insensitive to adherence with screening and costs of treating end-stage renal disease.
Conclusions: Treating all middle-aged diabetic patients with angiotensin-converting enzyme inhibitors is a simple strategy that provides additional benefit at modest additional cost. The strategy assumes that patients meet the older diagnostic criteria for diabetes and makes sense only for those who are not bothered by treatment.
Author and Article Information
From the Department of Veterans Affairs Medical Center, White River Junction, Vermont.
Acknowledgments: The authors thank the members of the Veterans Affairs Outcomes Group for intellectual support and encouragement.
Grant Support: Dr. Golan was supported by the Veterans Affairs Fellowship in Ambulatory Care. Dr. Birkmeyer was supported by a Career Development Award from the Veterans Affairs Health Services Research and Development Program.
Requests for Reprints: H. Gilbert Welch, MD, MPH, Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, VT 05009-0001. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Golan: Vondrousova 1156, 163000 Prague 6, Reply II, Czech Republic.
Drs. Birkmeyer and Welch: Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, VT 05009-0001. ARTICLE
The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors
7.8 mmol/L [140 mg/dL]).
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. J. Postma, C. Boersma, and R. T. Gansevoort Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1103 - 1106. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Palmer, W. J. Valentine, R. Chen, N. Mehin, S. Gabriel, B. Bregman, and R. A. Rodby A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1216 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Jaar, R. Khatib, L. Plantinga, L. E. Boulware, and N. R. Powe Principles of Screening for Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 601 - 609. [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Campbell, K. D Boardman, M. A Dodd, and D. W Raisch Pharmacoeconomic Analysis of Angiotensin-Converting Enzyme Inhibitors in Type 2 Diabetes: A Markov Model Ann. Pharmacother., July 1, 2007; 41(7): 1101 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kiberd The Chronic Kidney Disease Epidemic: Stepping Back and Looking Forward J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2967 - 2973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Kimmel Update in nephrology and hypertension. Ann Intern Med, February 21, 2006; 144(4): 281 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Chapman, D. M. Mannino, J. B. Soriano, P. A. Vermeire, A. S. Buist, M. J. Thun, C. Connell, A. Jemal, T. A. Lee, M. Miravitlles, et al. Epidemiology and costs of chronic obstructive pulmonary disease Eur. Respir. J., January 1, 2006; 27(1): 188 - 207. [Full Text] [PDF]
|
|
|
|
|
|
A. B. Rosen, M. B. Hamel, M. C. Weinstein, D. M. Cutler, A. M. Fendrick, and S. Vijan Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes Ann Intern Med, July 19, 2005; 143(2): 89 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Baskar, D. Kamalakannan, B. Kiberd, M.R. Holland, and B.M. Singh Hypertension-based clinical risk strategies for detecting microalbuminuria in diabetes QJM, June 1, 2005; 98(6): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang, M. M. Engelgau, S. L. Norris, E. W. Gregg, and K. M. Venkat Narayan Application of Economic Analysis to Diabetes and Diabetes Care Ann Intern Med, June 1, 2004; 140(11): 972 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hayward, T. P. Hofer, E. A. Kerr, and S. L. Krein Quality Improvement Initiatives: Issues in moving from diabetes guidelines to policy Diabetes Care, May 1, 2004; 27(suppl_2): B54 - B60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abbott, E. Basta, and G. L. Bakris Blood Pressure Control and Nephroprotection in Diabetes J. Clin. Pharmacol., April 1, 2004; 44(4): 431 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Hollenberg Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy: What Do We Know, and What Do We Need to Learn? Arch Intern Med, January 26, 2004; 164(2): 125 - 130. [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Boulware, B. G. Jaar, M. E. Tarver-Carr, F. L. Brancati, and N. R. Powe Screening for Proteinuria in US Adults: A Cost-effectiveness Analysis JAMA, December 17, 2003; 290(23): 3101 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Simpson, P. Corabian, P. Jacobs, and J. A. Johnson The cost of major comorbidity in people with diabetes mellitus Can. Med. Assoc. J., June 24, 2003; 168(13): 1661 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M Ruilope, J. Segura, and E. L Schiffrin Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients? Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 74 - 79. [Abstract] [PDF]
|
|
|
|
|
|
M. Tonelli, L. Moye, F. M. Sacks, T. Cole, and G. C. Curhan Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1605 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Krumholz, W. S. Weintraub, W. D. Bradford, P. A. Heidenreich, D. B. Mark, and A. D. Paltiel Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it? J. Am. Coll. Cardiol., August 21, 2002; 40(4): 603 - 615. [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Hostetter Prevention of End-Stage Renal Disease Due to Type 2 Diabetes N. Engl. J. Med., September 20, 2001; 345(12): 910 - 912. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Bruns Laboratory-related Outcomes in Healthcare Clin. Chem., August 1, 2001; 47(8): 1547 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. NISSENSON, A. J. COLLINS, J. HURLEY, H. PETERSEN, B. J. G. PEREIRA, and E. P. STEINBERG Opportunities for Improving the Care of Patients with Chronic Renal Insufficiency: Current Practice Patterns J. Am. Soc. Nephrol., August 1, 2001; 12(8): 1713 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Jafar, C. H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B. M. Brenner, A. Kamper, P. Zucchelli, et al. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data Ann Intern Med, July 17, 2001; 135(2): 73 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Melville, R Richardson, D Lister-Sharp, and A McIntosh Complications of diabetes: renal disease and promotion of self-management Qual. Saf. Health Care, December 1, 2000; 9(4): 257 - 263. [Full Text]
|
|
|
|
 |
|
 K. Malmberg and L. Ryden Ramipril reduced mortality and cardiovascular morbidity in high risk adults Evid. Based Med., March 1, 2000; 5(2): 47 - 47. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Cook and G. H. Guyatt Interpreting, Integrating, and Individualizing Evidence about the Prevention of Diabetic Nephropathy Ann Intern Med, November 2, 1999; 131(9): 707 - 708. [Full Text] [PDF]
|
|
